Volume 5, Supplement 2SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
Volume 5, Supplement 2SupplementE-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent Nonmetastatic Prostate Cancer...Robert DreicerMichael CarducciProstate cancerDocetaxelEstramustineKetoconazole
Volume 5, Supplement 3SupplementInnovative Therapies for Prostate Cancer TreatmentSamira SyedAnthony TolcherDocetaxelHormone-refractory prostate cancerAntisense oligonucleotides
Volume 5, Supplement 3SupplementA New Paradigm for the Treatment of High-Risk Prostate Cancer: Radiosensitization with DocetaxelParvesh KumarProstate cancerDocetaxelThree-dimensional conformal radiation therapyRadiosensitization
Volume 5, Supplement 3SupplementDocetaxel and Thalidomide as a Treatment Option for Androgen-Independent, Nonmetastatic Prostate CancerWilliam L DahutGregory D LeonardWilliam D FiggPhilip M ArlenJames L GulleyDocetaxelAndrogen-independent prostate cancerThalidomidePalliative
Volume 5, Supplement 3SupplementE-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer...Robert DreicerMichael CarducciProstate cancerDocetaxelEstramustineKetoconazole
Volume 5, Supplement 3SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
Volume 7, Number 1Meeting ReviewsProstate Cancer Update: 2004Alan W PartinStephen J FreedlandProstate cancerChemotherapyHigh-intensity focused ultrasoundDocetaxelFinasterideDutasteride
Volume 8, Supplement 2Review ArticlesThe Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond16th International Prostate Cancer UpdateDaniel P PetrylakTwo randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer. [Rev Urol. 2006;8(suppl 2):S48-S55]Prostate cancerProstate-specific antigenAndrogen ablationDocetaxelEstramustineEndothelin receptor antagonist
Volume 9, Supplement 2Review ArticlesNew Paradigms for Advanced Prostate CancerAndrogen-Independent Prostate CancerDaniel P PetrylakIn men with metastatic hormone-refractory prostate cancer, androgen blockade produces dramatic and rapid declines in prostate-specific antigen (PSA), bone pain, and urinary tract obstruction. Nevertheless, there have been limited options with at best palliative results for patients who progress despite a castrate testosterone level. This paradigm changed in 2004 with the publication of 2 randomized clinical trials that demonstrated a 20% to 24% survival benefit for docetaxel-based therapy when compared to mitoxantrone and prednisone, data that supported US Food and Drug Administration approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer. This article reviews the preliminary data and the timing and sequencing implications of ongoing clinical trials. Studies are evaluating the combination of docetaxel with agents that target bone, tumor vasculature, and the vitamin D receptor as well as second-line agents, such as satraplatin. The role of immune therapy is also evolving, and further studies will define the optimal timing of chemotherapy with immune therapy. [Rev Urol. 2007;9(suppl 2):S3-S12]Prostate cancerDocetaxelHormone-refractory prostate cancerAndrogen-independent prostate cancer